These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

718 related items for PubMed ID: 23522121

  • 1. Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
    Meloni AR, DeYoung MB, Han J, Best JH, Grimm M.
    Cardiovasc Diabetol; 2013 Mar 23; 12():48. PubMed ID: 23522121
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.
    Trautmann ME, Van Gaal L, Han J, Hardy E.
    J Diabetes Complications; 2017 Sep 23; 31(9):1415-1422. PubMed ID: 28669463
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
    Diamant M, Van Gaal L, Guerci B, Stranks S, Han J, Malloy J, Boardman MK, Trautmann ME.
    Lancet Diabetes Endocrinol; 2014 Jun 23; 2(6):464-73. PubMed ID: 24731672
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z.
    J Diabetes; 2017 Sep 23; 9(9):814-816. PubMed ID: 28589542
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
    Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M.
    Lancet; 2010 Jun 26; 375(9733):2234-43. PubMed ID: 20609969
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
    Guja C, Frías JP, Somogyi A, Jabbour S, Wang H, Hardy E, Rosenstock J.
    Diabetes Obes Metab; 2018 Jul 26; 20(7):1602-1614. PubMed ID: 29473704
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.
    Clin Ther; 2007 Nov 26; 29(11):2333-48. PubMed ID: 18158075
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
    Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG, GWAA Study Group.
    Ann Intern Med; 2005 Oct 18; 143(8):559-69. PubMed ID: 16230722
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.
    Diamant M, Van Gaal L, Stranks S, Guerci B, MacConell L, Haber H, Scism-Bacon J, Trautmann M.
    Diabetes Care; 2012 Apr 18; 35(4):683-9. PubMed ID: 22357185
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.